Autopsy report · NCT00813514
Does Vascular Endothelial Growth Factor (VEGF) or Complement Factor H Gene Polymorphism Play a Role in the Treatment Success With VEGF Inhibitors in Patients With Choroidal NeoVascularization (CNV)?
Cause of deathNo reason given
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Na
- Sponsor
- Medical University of Vienna
- Sponsor type
- University, hospital or other
- Conditions
- Choroidal NeoVascularization; Age-Related Macular Degeneration
- Interventions
- VEGF genotyping
- Participants
- 0
- Sites
- 1
- Countries
- Austria
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.